KR20240116826A - 헤모글로빈의 조정제의 투여 방법 - Google Patents

헤모글로빈의 조정제의 투여 방법 Download PDF

Info

Publication number
KR20240116826A
KR20240116826A KR1020247023029A KR20247023029A KR20240116826A KR 20240116826 A KR20240116826 A KR 20240116826A KR 1020247023029 A KR1020247023029 A KR 1020247023029A KR 20247023029 A KR20247023029 A KR 20247023029A KR 20240116826 A KR20240116826 A KR 20240116826A
Authority
KR
South Korea
Prior art keywords
compound
day
pharmaceutically acceptable
acceptable salt
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247023029A
Other languages
English (en)
Korean (ko)
Inventor
얼라인 바스
켄 더친
카를라 비. 워싱턴
아서 로
Original Assignee
글로벌 블러드 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글로벌 블러드 테라퓨틱스, 인크. filed Critical 글로벌 블러드 테라퓨틱스, 인크.
Publication of KR20240116826A publication Critical patent/KR20240116826A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247023029A 2021-12-10 2022-12-09 헤모글로빈의 조정제의 투여 방법 Pending KR20240116826A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163288377P 2021-12-10 2021-12-10
US63/288,377 2021-12-10
US202263421524P 2022-11-01 2022-11-01
US63/421,524 2022-11-01
US202263429376P 2022-12-01 2022-12-01
US63/429,376 2022-12-01
PCT/US2022/052411 WO2023107697A1 (en) 2021-12-10 2022-12-09 Methods of administering a modulator of hemoglobin

Publications (1)

Publication Number Publication Date
KR20240116826A true KR20240116826A (ko) 2024-07-30

Family

ID=85108880

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247023029A Pending KR20240116826A (ko) 2021-12-10 2022-12-09 헤모글로빈의 조정제의 투여 방법

Country Status (10)

Country Link
US (1) US20250041312A1 (https=)
EP (1) EP4444285A1 (https=)
JP (1) JP2024545496A (https=)
KR (1) KR20240116826A (https=)
AU (1) AU2022408097B2 (https=)
CA (1) CA3241881A1 (https=)
IL (1) IL312835A (https=)
MX (1) MX2024007064A (https=)
TW (1) TW202339732A (https=)
WO (1) WO2023107697A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4727555A1 (en) * 2023-06-13 2026-04-22 Global Blood Therapeutics, Inc. (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
PT3880654T (pt) * 2018-11-19 2022-04-08 Global Blood Therapeutics Inc Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina
EP4337659A1 (en) * 2021-05-14 2024-03-20 Global Blood Therapeutics, Inc. Solid forms of a modulator of hemoglobin

Also Published As

Publication number Publication date
AU2022408097B2 (en) 2026-03-12
TW202339732A (zh) 2023-10-16
US20250041312A1 (en) 2025-02-06
CA3241881A1 (en) 2023-06-15
EP4444285A1 (en) 2024-10-16
MX2024007064A (es) 2024-06-20
AU2022408097A1 (en) 2024-05-30
IL312835A (en) 2024-07-01
JP2024545496A (ja) 2024-12-09
WO2023107697A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
KR101913442B1 (ko) 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
EP2275108A1 (en) Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form
EP3437644A1 (en) Medicine
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
KR20240116826A (ko) 헤모글로빈의 조정제의 투여 방법
TWI646960B (zh) 慢性腎臟病之進展抑制或改善用製劑
US20220185791A1 (en) Polymorphs of a cardiac troponin activator
CN119156211A (zh) 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
RU2855050C2 (ru) Способы введения модулятора гемоглобина
EP1772149A1 (en) Drug for prevention or treatment of diabetes
EP2703400A1 (en) Phenyl pyrrole derivative crystal
EP3646864B1 (en) Pharmaceutical containing pemafibrate
CN108771662A (zh) 紫檀芪在制备防治高尿酸肾病的药物中的用途
WO2024256964A1 (en) (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease
CN118369092A (zh) 施用血红蛋白调节剂的方法
HK40107036A (zh) 施用血红蛋白调节剂的方法
SG185474A1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
EA018442B1 (ru) Применение l-карнитина для лечения гипертензии, для снижения систолического или пульсового давления крови у субъектов с предиабетом
AU2002328569B9 (en) Medicinal compositions containing angiotensin II receptor antagonist
EP3389660B1 (en) Combination therapy for cancer
KR101436547B1 (ko) 고지혈증의 예방 또는 치료용 약학 조성물
DK2271327T3 (en) Pharmaceutical composition comprising rhymeporide for the treatment of diseases associated with beta-cell dysfunction
JP4925406B2 (ja) 糖尿病性腎症の予防及び／又は治療剤
JP2023177335A (ja) がん治療のための併用療法
JP2006045142A (ja) ＮＣＸ１阻害剤を含有する、内因性Ｎａ＋ポンプ抑制物質と関連する循環障害の治療薬または診断用薬

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902